MedTrace Logo

Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration

NCT06487039 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-08-27

No results posted yet for this study

Summary

Trial to Evaluate the Safety and Efficacy of EB-203 in Patients with Neovascular Age-related Macular Degeneration.

The purpose of this study is to primarily investigate the safety and tolerability of EB-203 by dose in patients with neovascular Age-related Macular Degeneration (nAMD), and to secondarily evaluate the clinical efficacy. Subject to Adults aged 50 years or older and Neovascular age-related macular degeneration (nAMD)

Conditions

  • Neovascular Age-related Macular Degeneration (nAMD)

Interventions

DRUG

EB-203

Subjects will receive EB-203 according to the following dosage and administration method for each treatment group.

Sponsors & Collaborators

  • EyebioKorea, Inc.

    lead INDUSTRY

Principal Investigators

  • Kyu Hyeong Park · Seoul National University HospitalSeoul National University Hospital

  • JaeHui Kim · Kim's Eye Hospital

  • Iksoo Byon · Pusan National University Hospital

  • Min Sagong · Yeungnam University Hospital

  • Dong Geun Kim · Inje University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2025-08-31
Completion
2026-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06487039 on ClinicalTrials.gov